3SBio Inc
Hao Zhang is a seasoned professional in the pharmaceutical and biotechnology industries with extensive experience in corporate development and clinical research. Currently serving as the Head of Corporate Development at 3SBio Inc. since March 2022, Zhang has previously held key positions at notable companies, including Chief Development Officer at SinoMab Bioscience Ltd. and Global Clinical Development Strategy Lead for China/APAC at Baxter International Inc. Zhang's career also includes significant roles at Pfizer, Sanofi, Johnson & Johnson R&D, and C-Bridge Capital, showcasing expertise in regional medical leadership and clinical research. Educational credentials include a Dr.med degree from the University of Zurich, an M.Sc. from KU Leuven, and two degrees from Zhejiang University.
This person is not in any teams
This person is not in any offices
3SBio Inc
3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Company's main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company's subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd. Through its subsidiaries, the Company is engaged in project management and consultation.